- 1 Title: Circulating polyunsaturated fatty acids and COVID-19: a prospective cohort study and 2 Mendelian randomization analysis
- 3
- 4 Yitang Sun¹, Radhika Chatterjee¹, Akash Ronanki¹, Kaixiong Ye^{1,2,*}
- 5
- 6 ¹Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens,
- 7 GA, USA; and ² Institute of Bioinformatics, University of Georgia, Athens, GA, USA
- 8

9 * Address for Correspondence:

- 10
- 11 Dr. Kaixiong Ye
- 12 Department of Genetics
- 13 University of Georgia
- 14 C220 Davison Life Sciences
- 120 East Green Street, Athens, GA 30602 15
- 16 Office: 706-542-5898
- 17 Fax: 706-542-3910
- 18 Email: Kaixiong.Ye@uga.edu

19 ABSTRACT

20 Background: Higher circulating polyunsaturated fatty acids (PUFAs), especially omega-3 ones,

21 have been linked to a better prognosis in patients of coronavirus disease 2019 (COVID-19).

22 However, the effects and causality of pre-infection PUFA levels remain unclear.

23 Objective: To investigate the observational and causal associations of circulating PUFAs with

24 COVID-19 susceptibility and severity.

25 **Design:** We first performed a prospective cohort study in UK Biobank, with 20,626 controls who 26 were tested negative and 4,101 COVID-19 patients, including 970 hospitalized ones. Plasma 27 PUFAs at baseline were measured by nuclear magnetic resonance, including total PUFAs, omega-28 3 PUFAs, omega-6 PUFAs, docosahexaenoic acid (DHA), linoleic acid (LA), and the omega-29 6/omega-3 ratio. Moreover, bidirectional two-sample Mendelian randomization (MR) analyses 30 were performed to examine the causal associations of eight individual PUFAs, measured in either 31 plasma or red blood cells, with COVID-19 susceptibility and severity using summary statistics 32 from existing genome-wide association studies.

33 **Results:** In the observational association analysis, total PUFAs, omega-3 PUFAs, omega-6 PUFAs, 34 DHA, and LA were associated with a lower risk of severe COVID-19. Omega-3 PUFAs and DHA 35 were also associated with a lower risk of testing positive for COVID-19. The omega-6/omega-3 36 ratio was positively associated with risks of both susceptibility and severity. The forward MR 37 analysis indicated that arachidonic acid (AA) and docosapentaenoic acid (DPA-n3) might be 38 causally associated with a lower risk of severe COVID-19, with OR (95% CI) per one SD increase 39 in the plasma level as 0.96 (0.94, 0.99) and 0.89 (0.81, 0.99), respectively. The reverse MR analysis 40 did not support any causal effect of COVID-19 on PUFAs.

- 41 Conclusions: Our observational analysis supported that higher circulating PUFAs, either omega-
- 42 3 or omega-6, are protective against severe COVID-19, while omega-3 PUFAs, especially DHA,
- 43 were also associated with reducing COVID-19 susceptibility. Our MR analysis further supported
- 44 causal associations of AA and DPA-n3 with a lower risk of severe COVID-19.

45

- 46 Key Words: COVID-19; polyunsaturated fatty acids; Mendelian randomization; prospective
- 47 cohort; docosapentaenoic acid; arachidonic acid

48 Introduction

49 The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory 50 syndrome coronavirus 2 (SARS-CoV-2), has resulted in over five million deaths in less than two 51 years (1, 2). Understanding the role of nutrition in moderating susceptibility to and progression of 52 COVID-19 is critical for the development of evidence-based dietary recommendations to prevent 53 infection and to manage disease progression (3, 4). Omega-3 and omega-6 polyunsaturated fatty 54 acids (PUFAs) are of special interest because of their potent immunomodulatory effects, not only 55 in mounting immune responses against viral infection but also in promoting inflammation 56 resolution to avoid tissue damage (5-7). COVID-19 is an infectious disease characterized by 57 cytokine storm and hyperinflammation in severe cases (8), presenting multiple possible points of 58 action for PUFAs.

59

60 Recent observational studies have noted significant changes in the circulating levels of various 61 PUFAs when comparing COVID-19 patients to healthy controls and across severity subgroups of 62 patients. In general, total PUFAs, omega-6 PUFAs, linoleic acid (LA), and the omega-3 index 63 measured as the percentage of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in 64 red blood cell (RBC) fatty acids, are lower in COVID-19 patients and even lower in severe cases 65 (9-12). A higher omega-3 index in patients was further associated with lower risks of requiring 66 mechanical ventilation and death (9, 10). But conflicting patterns were also reported across cohorts 67 and studies (11, 12), such as elevated levels of LA and arachidonic acid (AA) in COVID-19 68 patients (12). Moreover, the circulating levels of PUFAs in patients are likely confounded by 69 immune responses to the viral infection and do not represent the effects of pre-infection circulating 70 levels. There is a prospective cohort study that compared hospitalized COVID-19 patients to non-

71 cases and found that almost all PUFA measurements, including total PUFAs, omega-6 PUFAs, 72 omega-3 PUFAs, LA, and DHA, are associated with a lower risk of severe COVID-19. The only 73 exception is the omega-6/omega-3 ratio, which exhibits a positive association (13). However, the 74 study did not distinguish the effects on susceptibility and severity, and the usage of non-cases 75 without COVID-19 status as the control did not correct for selection bias in those receiving tests. 76 Altogether, while these observational studies provide valuable insights, they are susceptible to 77 residual confounding and reverse causation. The causal effects of circulating PUFAs on COVID-78 19 susceptibility and severity remain unclear.

79

80 Mendelian randomization (MR) is an analytic tool for inferring the causal effects of an exposure 81 on an outcome of interest (14). MR uses randomly allocated genetic variants related to the exposure 82 as instrumental variables, which are inborn and minimally affected by confounders and reverse 83 causation (15). This method has been widely utilized in recent studies to evaluate the causal roles 84 of specific risk factors in COVID-19, such as body mass index (BMI), white blood cells, some 85 circulating proteins, and smoking (16-19). On the other hand, MR studies have also provided 86 support for the causal clinical effects of circulating PUFAs (Supplemental Table 1). The 87 genetically predicted circulating levels of various PUFAs have been associated with clinical 88 biomarkers, such as blood lipids, white blood cell counts, and blood pressure (20-22). They were 89 also directly associated with risks of specific diseases, such as cardiovascular diseases, diabetes, 90 and cancers (23-27). Therefore, MR is a valuable and cost-effective tool to evaluate the causal 91 roles of circulating PUFAs in COVID-19 susceptibility and severity.

92

93 In this study, we first performed an observational analysis in a prospective cohort, UK Biobank, 94 with 4,101 COVID-19 patients, including 970 hospitalized ones, and 20,626 controls that were 95 tested negative. We performed multiple comparisons across different case and control groups to 96 evaluate the effects of six baseline plasma PUFA measures on COVID-19 susceptibility and 97 severity. Furthermore, we applied bidirectional two-sample MR analyses to examine the causal 98 associations between eight individual PUFAs and COVID-19. Genetic instruments for circulating 99 PUFAs were obtained from previous genome-wide association studies (GWAS) of corresponding 100 PUFAs measured in either plasma or RBC (28-30). Genetic associations with COVID-19 101 susceptibility and severity were obtained from GWAS meta-analyses conducted by the COVID-102 19 Host Genetics Initiative (HGI) (31). Our study, integrating observational and genetics-103 instrumented MR analyses, unraveled the effects of total and individual circulating PUFAs on the 104 risks of COVID-19 susceptibility and severity.

105 Methods

106 **Ethical considerations**

107 The usage of individual-level data for this study was approved by the University of Georgia 108 Institutional Review Board and UK Biobank (application no. 48818). All participants of UK 109 Biobank and the Framingham Heart Study (FHS) provided written informed consent before joining 110 these studies. Informed consent was not required for publicly available summary statistics. Our 111 study follows the guidelines for strengthening the reporting of observational studies in 112 epidemiology (STROBE, Supplemental Table 2) and strengthening the reporting of Mendelian 113 randomization studies (STROBE-MR, Supplemental Table 3) (32).

114

115 Participants and study design

116 We performed an observational cohort study based on UK Biobank and then a bidirectional two-117 sample MR study with summary statistics from GWAS of PUFAs and COVID-19. UK Biobank 118 is a population-based prospective study, including >500,000 participants aged 37–73 years at 119 recruitment from 2006 to 2010 in the United Kingdom (33). The observational analysis was 120 performed to examine the associations between six plasma PUFA measures and COVID-19 status 121 in UK Biobank. The six plasma PUFA measures include total PUFAs, omega-3 PUFAs, omega-6 122 PUFAs, DHA, LA, and the calculated omega-6/omega-3 ratio. The MR study investigated the 123 causal effects of eight individual PUFAs on COVID-19 susceptibility and severity. Genetic 124 instruments for plasma PUFAs were obtained directly from published GWAS (28, 29). Genetic 125 instruments for RBC PUFAs were determined based on a published GWAS, but their summary 126 statistics, not reported in the original study, were calculated by ourselves with the same statistical 127 model and individual-level data from 2,462 FHS participants (30). Six PUFAs have genetic

128 instruments for their circulating levels in both plasma and RBC, including α-Linolenic acid (ALA),

129 docosapentaenoic acid (DPA-n3), LA, γ-Linoleic acid (GLA), dihomo-γ-linoleic acid (DGLA),

130 and AA. Docosatetraenoic acid (DTA) only has genetic instruments for its RBC level, while DHA

131 only for its plasma level.

132

133 **Observational analysis**

134 Figure 1 displays the flow of participants throughout the observational study. To minimize the 135 possibility of bias due to population stratification, the analysis was restricted to individuals of 136 European descent. In addition, we removed participants who had mismatched self-reported sex 137 and genetic sex, sex chromosome aneuploidy, ten or more third-degree or closer relatives, or had 138 withdrawn from UK Biobank. Our exposure variables were six PUFAs, as measured by nuclear 139 magnetic resonance (NMR) in plasma samples collected between 2007 and 2010 (13, 33, 34). We 140 used the COVID-19 testing result and inpatient status as our outcome (data accessed on June 21, 141 2021). The specimen collection dates were March 16, 2020 to June 14, 2021 for those in England; 142 February 11, 2020 to March 18, 2021 in Scotland; and January 13, 2020 to June 7, 2021 in Wales. 143 Hospitalized COVID-19 patients were identified as those with positive PCR-based diagnosis and 144 explicit evidence of being inpatients. Of note, being an inpatient does not necessarily indicate 145 hospitalization for COVID-19 because patients in hospitals for any reason may be prioritized for 146 COVID-19 testing (35). Inpatient status was not available for assessment centers in Scotland and 147 Wales. To test the association with COVID-19 severity, we performed two separate analyses with 148 different controls: 1) non-hospitalized COVID-19 patients, and 2) individuals who tested negative. 149 To examine the association with COVID-19 susceptibility, we focused on all COVID-19 cases 150 which were tested positive for SARS-CoV-2. Individuals with negative tests were used as the

151 control. This analysis of susceptibility was performed in two datasets: 1) participants from England, 152 and 2) participants from England, Scotland, and Wales. For the 24,727 participants with both 153 plasma PUFA measures and COVID-19 status, we applied logistic regression models on various 154 case and control groups to estimate the associations of PUFAs with COVID-19 susceptibility and 155 severity. Covariates included continuous variables, age, BMI, and Townsend deprivation index, 156 and categorical variables, sex, ethnicity, and assessment center. Individuals with missing 157 information in PUFA measures, COVID-19 status, or covariates were excluded. The comparable 158 effect sizes were expressed per one standard deviation (SD) increase in the plasma PUFAs. All 159 analyses in the observational study were conducted using R version 4.0.0, and nominal 160 significance was set at p-value < 0.05. Bonferroni correction for multiple testing [corrected P 161 significance cutoff: 0.05/2 (outcomes)/6 (exposures) = 0.0042] was used to avoid the type I error 162 (36).

163

164 Genetic associations with PUFAs

165 Two types of circulating PUFAs were evaluated in our MR analyses, plasma and RBC PUFAs. 166 For plasma PUFAs, single nucleotide polymorphisms (SNPs) were obtained from published 167 GWAS of omega-3 PUFAs (n = 8,866) and omega-6 PUFAs (n = 8,631) in participants of 168 European ancestry (28, 29). We selected SNPs for each plasma omega-3 and omega-6 PUFA, which reached genome-wide significance level ($P < 5 \times 10^{-8}$) and were restricted by linkage 169 170 disequilibrium (LD) clumping to ensure independence ($R^2 < 0.001$ within a 10 Mb window). To 171 ensure robustness and reduce false positives, we also used less stringent LD cutoffs ($R^2 < 0.01$, 172 0.1, and 0.3) to select SNPs associated with plasma omega-3 PUFAs. The same LD-related 173 sensitivity analysis was not possible for plasma omega-6 PUFAs because their genome-wide

174 summary statistics were not available. To examine the effects of RBC PUFAs, we obtained genetic 175 associations at a genome-wide significance level ($P < 5 \times 10^{-8}$) identified by Tintle *et al.* (30). We 176 used the individual-level data from the FHS to confirm the significance of these SNPs and calculate 177 their effect sizes and standard errors. In the same linear mixed model, covariates included age, sex, 178 and matrix of kinship coefficients in the FHS. We respectively selected independent ($R^2 < 0.001$, 179 0.01, 0.1, and 0.3 within a 10 Mb window) SNPs predicting RBC PUFAs at genome-wide 180 significance ($P < 5 \times 10^{-8}$). We calculated F-statistics to test instrument strength (F-statistics >10) 181 for all plasma and RBC PUFAs) (37). Summary statistics for the genetic instruments for plasma 182 and RBC PUFAs are openly available for public access (Supplemental Tables 4 and 5).

183

184 Genetic associations with COVID-19

185 To assess genetic associations with COVID-19 severity, we used three GWAS meta-analyses 186 conducted by the HGI (release 5, released on January 18, 2021) (31). First, we used the GWAS of 187 severe COVID-19, labeled as study A2, that compared patients confirmed with very severe 188 respiratory symptoms (n = 5,101) to the control group of general population samples (n =189 1,383,241). Second, another HGI GWAS, labeled as study B2, compared hospitalized COVID-19 190 patients (n = 9,986) to general population samples (n = 1,877,672). The third severe COVID-19 191 GWAS utilized in our study, labeled as B1, compared hospitalized COVID-19 patients (n = 4,829) 192 to non-hospitalized COVID-19 patients (n = 11,816). To assess genetic associations with COVID-193 19 susceptibility, we used one GWAS by HGI, labeled as study C2, that compared any COVID-194 19 case (n = 38,984) to population controls (n = 1,644,784). In addition to these four COVID-19 195 GWAS used in our primary analysis, we repeated MR analyses using the study A2, B1, B2, and 196 C2 from HGI release 4 (released on October 20, 2020), to examine the consistency of our findings

197 across different data releases. Detailed information about these GWAS is available at the COVID-

198 19 HGI website (<u>https://www.covid19hg.org/results/</u>).

199

200 To assess reverse causality, we obtained strong ($P < 5 \times 10^{-8}$) and independent ($R^2 < 0.001$ within

a 10 Mb clumping window) SNPs associated with COVID-19 phenotypes as genetic instruments.

We also used a less stringent selection criterion ($P < 5 \times 10^{-6}$) to determine the robustness of our results.

204

205 MR analyses

206 MR was used to infer causality between PUFAs and COVID-19 by leveraging genetic data as 207 instrumental variables. We scaled the odds ratio (OR) estimates per SD increment of plasma and 208 RBC PUFAs (% of total fatty acids). We obtained the SNP-specific Wald estimate (ratio of the 209 SNP-outcome effect divided by the SNP-exposure effect) when only one SNP was available. The 210 inverse variance-weighted (IVW) method with a multiplicative random-effects model (≥ 2 SNPs) 211 was used as the primary analysis (38-40). We used the MR-Egger intercept test to evaluate the 212 extent of unbalanced horizontal pleiotropy, which can lead to a biased causal effect estimate (39). 213 In sensitivity analyses, we applied the MR-Egger and weighted median (WM) methods to account 214 for pleiotropy (39-41). The MR-Egger method provides an unbiased causal estimate even when all 215 SNPs are invalid instruments as long as that the horizontal pleiotropic effects are balanced across 216 SNPs (39). However, MR-Egger can be imprecise and suffer from low statistical power, 217 particularly when based on a small number of SNPs (e.g., < 10) (39). The WM method gives robust 218 causal estimates even when up to 50% of SNPs are invalid genetic instruments (41). To test the 219 presence of heterogeneity among genetic instruments, we calculated Cochran's Q statistic for the

- 220 IVW method and an extended version of Cochran's Q statistic (Rücker's Q') for the MR-Egger
- 221 method (42, 43). We utilized Bonferroni correction [corrected P significance cutoff: 0.05/2
- (outcomes)/7 (exposures) = 0.0036] for multiple testing. Additionally, we required a relationship
- to be nominally significant (P < 0.05) with both measures of the same PUFA (plasma and RBC)
- and in the case of COVID-19 severity, with different outcome GWAS (study A2, B2, and B1). All
- 225 MR analyses were performed in R version 4.0.0 with the TwoSampleMR package version 3.6.9

226 (44).

227 Results

228 **Baseline characteristics**

229 The flow of UK Biobank participants throughout the observational study is described in Figure 1,

- 230 while their baseline characteristics are summarized in Table 1. Across all assessment centers in
- 231 England, Scotland, and Wales, there were 104,112 participants with COVID-19 status. Among
- them, 17,395 were tested positive for COVID-19. Inpatient status was only reported by assessment
- 233 centers in England. Of the 92,756 participants with COVID-19 status in England, 16,449 were
- tested positive, and 4,209 had confirmed inpatient status. Across England, Scotland, and Wales,
- COVID-19 patients were more likely to be male (t-test, P = 0.008), with higher BMI ($P = 9.34 \times 10^{-14}$), but younger than participants with negative testing results ($P < 2.2 \times 10^{-16}$). Across assessment centers in England, hospitalized COVID-19 patients were older ($P < 2.2 \times 10^{-16}$), were more likely to be male ($P = 2.44 \times 10^{-5}$), and had higher BMI ($P = 1.13 \times 10^{-14}$), when compared
- to non-hospitalized COVID-19 patients.
- 240

241 **Observational association analysis**

242 Table 2 shows the observational associations between baseline plasma PUFAs and COVID-19 243 susceptibility and severity. Among participants from England who also had plasma data, there 244 were 18,293 with negative testing results and 3,873 with positive tests. Among the COVID-19 245 patients, 970 were hospitalized and the other 2,903 were non-hospitalized. Comparing hospitalized 246 patients to those tested negative, we observed a lower risk of COVID-19 severity per SD increase in total PUFAs (OR: 0.88; 95% confidence interval (CI): 0.82, 0.95; P = 0.0005), omega-3 PUFAs 247 (OR: 0.82; 95% CI: 0.76, 0.89; $P = 8.1 \times 10^{-7}$), omega-6 PUFAs (OR: 0.91; 95% CI: 0.85, 0.98; 248 P = 0.0121), DHA (OR: 0.78; 95% CI: 0.72, 0.85; $P = 4.6 \times 10^{-9}$), and LA (OR: 0.92; 95% CI: 249

250 0.86, 0.99; P = 0.0228). Using 2,903 non-hospitalized COVID-19 patients as the control group, 251 there were consistently inverse associations of COVID-19 severity with total PUFAs (P = 0.0012), 252 omega-3 PUFAs (P = 0.0013), omega-6 PUFAs (P = 0.0047), DHA ($P = 8.9 \times 10^{-5}$), and LA (P253 = 0.0079).

254

We further evaluated the effects of baseline plasma PUFAs on COVID-19 susceptibility by comparing COVID-19 patients to those tested negative. Among 24,727 participants in England, Scotland, and Wales, we found a lower risk of getting COVID-19 per SD increase in omega-3 PUFAs (OR: 0.92; 95% CI: 0.89, 0.96; $P = 2.3 \times 10^{-5}$) and DHA (OR: 0.91; 95% CI: 0.87, 0.94; $P = 1.4 \times 10^{-6}$). Among 22,166 individuals in England only, we also observed consistently significant associations for omega-3 PUFAs (OR: 0.92; 95% CI: 0.88, 0.96; $P = 4.3 \times 10^{-5}$) and DHA (OR: 0.91; 95% CI: 0.87, 0.94; $P = 3.0 \times 10^{-6}$).

262

263 The omega-6/omega-3 ratio was significantly associated with an increased risk of severe COVID-264 19, either by comparing hospitalized patients to participants who tested negative (OR: 1.13; 95% CI: 1.07, 1.20; $P = 1.5 \times 10^{-5}$) or to non-hospitalized patients (OR: 1.12; 95% CI: 1.03, 1.22; P =265 266 0.0061). The ratio was also positively associated with COVID-19 susceptibility when comparing 267 COVID-19 patients to those tested negative in England, Scotland, and Wales (OR: 1.06; 95% CI: 268 1.03, 1.10; P = 0.0005) or in England only (OR: 1.05; 95% CI: 1.02, 1.09; P = 0.0030). Overall, 269 our observational analysis showed that individuals with lower baseline levels of all five examined 270 PUFAs were associated with a higher risk of hospitalized COVID-19, and those with lower levels 271 of omega-3 PUFAs and DHA were also at a higher risk of COVID-19 susceptibility. On the other

hand, the omega-6/omega-3 ratio was positively associated with the risks of both COVID-19
susceptibility and severity.

274

275 Bidirectional MR analyses

276 We performed bidirectional MR analyses to examine the causal relationships between individual 277 PUFAs and COVID-19. First, we performed a forward MR analysis to investigate the effects of 278 PUFAs on COVID-19 susceptibility and severity. Second, we conducted a reverse MR analysis to 279 evaluate the causal effects of genetically instrumented COVID-19 on PUFAs. All genetic 280 instruments for PUFAs (F-statistics >31.43) and COVID-19 (F-statistics >30.81) were strong 281 instruments. Six individual PUFAs have existing GWAS for their levels in plasma and RBC, and 282 there are three GWAS on severe COVID-19 (i.e., HGI study A2, B2, B1). Only results that were 283 consistent across these different GWAS were reported here.

284

285 In the forward MR study of plasma PUFAs, genetically instrumented one-SD increase in AA (OR: 0.96; 95% CI: 0.94, 0.99; *P* = 0.007) and DPA-n3 (OR: 0.89; 95% CI: 0.81, 0.99; *P* = 0.026) were 286 287 associated with a lower risk of very severe respiratory symptoms of COVID-19 based on HGI 288 study A2 (Figure 2A). Consistently, genetically instrumented AA (OR: 0.96; 95% CI: 0.96, 0.97; $P = 3.23 \times 10^{-20}$) and DPA-n3 (OR: 0.93; 95% CI: 0.92, 0.95; $P = 4.73 \times 10^{-20}$) were associated 289 290 with a lower risk of hospitalized COVID-19 based on HGI study B2, which used general 291 population samples as the control (Figure 2B). Similar results were observed with HGI study B1, 292 which used non-hospitalized COVID-19 patients as the control (Figure 2C). Besides plasma 293 PUFAs, MR analyses with RBC PUFAs consistently support the protective effects of AA against 294 severe COVID-19 based on HGI A2 (OR: 0.97; 95% CI: 0.94, 1.00; P = 0.048), B2 (OR: 0.95;

295	95% CI: 0.93, 0.97; $P = 1.32 \times 10^{-5}$), and B1 (OR: 0.84; 95% CI: 0.83, 0.85; $P = 8.57 \times 10^{-130}$)
296	studies (Figures 2). For DPA-n3, its genetically instrumented RBC level was consistently
297	associated with a lower risk of COVID-19 severity in our forward MR analysis with study A2 (OR:
298	0.79; 95% CI: 0.63, 0.99; $P = 0.041$), B2 (OR: 0.88; 95% CI: 0.82, 0.94; $P = 9.30 \times 10^{-5}$), and B1
299	(OR: 0.76; 95% CI: 0.59, 0.98; $P = 0.036$) (Figures 2). To ensure the robustness of findings, we
300	selected genetic instruments based on various LD categories ($R^2 < 0.001$, 0.01, 0.1, and 0.3). The
301	causal estimates of AA and DPA-n3 were consistent and at least nominally significant throughout
302	all MR analyses (Supplemental Tables 6-8). Causal estimates for AA and DPA-n3 maintained the
303	same effect directions in MR-Egger and WM methods, and sensitivity tests identified no evidence
304	of horizontal pleiotropy or heterogeneity of effects (Supplemental Tables 6-8). Of note, while
305	there were nominally significant associations between plasma DHA and very severe COVID-19
306	with HGI A2 and between RBC DTA and hospitalized COVID-19 with HGI B1, these two
307	relationships were not replicated in analyses with the other two GWAS of severe COVID-19
308	(Figure 2).

309

In terms of COVID-19 susceptibility, we found that genetically instrumented one-SD increase of plasma DGLA (OR: 1.01; 95% CI: 1.00, 1.02; P = 0.031) was associated with an increased risk of any SARS-CoV-2 infection (Figure 3). MR analysis with RBC DGLA showed a similar pattern (OR: 1.01; 95% CI: 1.00, 1.02; P = 0.007). However, the association of genetically instrumented DGLA with the risk of testing positive for COVID-19 was not statistically significant using any other LD criteria for genetic instruments (Supplemental Table 9). Notably, our forward MR findings were confirmed using additional COVID-19 GWAS from HGI release 4 (Supplemental

- Tables 10–13). In summary, our forward MR analyses suggest that higher circulating levels of AA
 and DPA-n3 are associated with a lower risk of developing severe forms of COVID-19.
- 319
- 320 We further applied reverse MR analyses to investigate the causal effects of COVID-19 on each
- 321 PUFA. Although several reverse MR analyses showed that genetically instrumented COVID-19
- 322 susceptibility or severity was associated with ALA, DHA, GLA, or DGLA, there was no consistent
- 323 evidence for an effect of COVID-19 on these PUFAs using the conventional genome-wide
- 324 significance threshold ($P < 5 \times 10^{-8}$) and the more lenient threshold ($P < 5 \times 10^{-6}$) for COVID-19
- 325 SNPs from HGI release 5 (Supplemental Tables 14-21). In addition, we used SNPs associated
- 326 with COVID-19 from HGI release 4, and we did not observe any causal effect of COVID-19 on
- 327 PUFAs (Supplemental Tables 22–29). Importantly, the reverse MR results showed no significant
- 328 association of genetically predicted COVID-19 severity with AA and DPA-n3, suggesting that the
- 329 significant forward MR results are unlikely to be confounded by reverse causation.

330 Discussion

Our observational analysis in a prospective cohort showed that total PUFAs, omega-3 PUFAs, omega-6 PUFAs, DHA, and LA in baseline plasma samples were inversely associated with the risk of severe COVID-19. There were also inverse associations of omega-3 PUFAs and DHA with COVID-19 susceptibility. In contrast, the omega-6/omega-3 ratio was positively associated with both COVID-19 susceptibility and severity. In our bidirectional two-sample MR analyses, we provided evidence for the potential causal roles of higher circulating AA and DPA-n3 in a lower risk of COVID-19 severity.

338

339 Our observational findings are broadly consistent with previous observational studies and a pilot 340 clinical trial. Julkunen et al. also examined the UK Biobank cohort, although with smaller sample 341 sizes and different controls. They showed that for total PUFAs, omega-3 PUFAs, omega-6 PUFAs, 342 DHA, and LA, their absolute levels and relative percentages in total fatty acids were both inversely 343 associated with the risk of severe COVID-19 when comparing patients to non-cases with unknown 344 COVID-19 status (13). Our study corrected for potential selection bias by restricting the analysis 345 to individuals with COVID-19 testing status and used those with negative tests or non-hospitalized 346 patients as the controls. We confirmed the same inverse association patterns for severe COVID-347 19. We further showed that omega-3 PUFAs and DHA were inversely associated with COVID-19 348 susceptibility. Another study investigated the metabolic fingerprint of COVID-19 severity in 581 349 samples from three cohorts, revealing inverse associations with severity for total PUFAs, omega-350 6 PUFAs, and LA. But inconsistent associations of omega-3 PUFAs, DHA, and the omega-351 6/omega-3 ratio were also observed across cohorts (11). Comparing the lipid profile of 42 severe 352 COVID-19 patients to 22 healthy subjects, a study by Perez-Torres et al. found that plasma GLA,

353 DGLA, and EPA were decreased in COVID-19 patients, but LA and AA were elevated (12). Two 354 small studies found that the omega-3 index was significantly lower in COVID-19 patients and was 355 inversely associated with risks of requiring mechanical ventilation and death (9, 10). The 356 differences in these observational studies are likely results of uncontrolled confounding factors or 357 the usage of patients at different disease stages. In support of the associated protective effect of 358 omega-3 fatty acids, the first randomized clinical trial of supplementing 1000 mg omega-3 fatty 359 acids in 128 critically ill COVID-19 patients showed that the intervention group has a significantly 360 higher one-month survival rate and improved respiratory and renal function (45). Altogether with 361 the existing literature, our study supports the protective effects of omega-3 fatty acids against the 362 development of severe COVID-19 and likely also against viral infection. There are probably 363 protective benefits of omega-6 fatty acids against severe COVID-19, but a high omega-6/omega-364 3 ratio may increase the risks of both COVID-19 susceptibility and severity.

365

366 In our MR study, we examined whether specific individual PUFAs play causal roles in COVID-367 19 susceptibility and severity. We found that genetically instrumented circulating levels of AA 368 and DPA-n3 are associated with a lower risk of severe COVID-19. AA is an omega-6 fatty acid, 369 while DPA-n3 is an omega-3 fatty acid. Although these two specific PUFAs were not available in 370 our observational analysis, their potentially causal protective effects are consistent with the inverse 371 associations of both omega-6 PUFAs and omega-3 PUFAs with severe COVID-19. The potential 372 protective roles of AA and DPA-n3 in severe COVID-19 have mechanistic support. Both of them 373 are well-known to serve as precursors of specialized pro-resolving mediators, such as lipoxins 374 derived from AA, resolvins, protectins and maresins derived from DPA-n3, playing essential roles 375 in promoting the resolution of inflammatory responses and tissue repair (5, 7, 46). Notably, it has

376 been highlighted that the roles of AA in initiating timely inflammatory responses through its 377 derived prostaglandins (PGs), such as PGE_2 , may be as important as its roles in inflammatory 378 resolution through lipoxins (6, 47). Another possible mechanistic route for AA could be drawn 379 from a human cell line study (48). Huh-7 cells, a hepatocyte-derived carcinoma cell line, when 380 infected with human coronavirus 229E (HCoV-229E), exhibit significantly elevated levels of LA 381 and AA, a pattern also observed in a study of severe COVID-19 patients (12). Interestingly, 382 exogenous supplementation of LA and AA in HCoV-229E-infected cells significantly suppressed 383 HCoV-229E virus replication. Similar suppressive effects were observed for the highly pathogenic 384 Middle East respiratory syndrome coronavirus (MERS-CoV) (48), suggesting a possible general 385 mechanism of LA and AA on coronavirus. Additionally, LA has been shown to directly and tightly 386 bind the SARS-CoV-2 spike glycoprotein, reducing its interaction with the human ACE2 receptor 387 (49). Similar inhibitory effects were observed for ALA, EPA, and DHA in a ligand screening study 388 (50), which did not include AA and DPA-n3. Our MR findings call for future studies into the 389 mechanistic roles of AA and DPA-n3 in the development of severe COVID-19.

390

391 Our study has a number of strengths and novel features. To our knowledge, this is the first MR 392 study examining the causal effects of PUFAs on COVID-19. It is also the first MR study of PUFAs 393 that used genetic variants for RBC PUFAs, in addition to plasma PUFAs. We applied bidirectional 394 two-sample MR analyses to evaluate the direction of the causality and to rule out the impacts of 395 reverse causation. To obtain robust evidence, we required the reported patterns to be observed with 396 both plasma and RBC PUFAs. Similarly, to ensure reproducibility across data releases, we 397 confirmed the results with analyses based on four COVID-19 GWAS (A2, B2, B1, and C2) from 398 HGI releases 5 and 4. Bonferroni correction was used to overcome the issue of multiple testing.

Another strength is the sensitivity analysis with various LD cutoffs. Additionally, comparing our
MR results between severe COVID-19 and any SARS-CoV-2 infection, we found that AA and
DPA-n3 might mainly impact the severity of disease progression but not susceptibility to viral
infection.

403

404 Our study has several limitations. First, we could not completely rule out the possibility that some 405 genetic variants might be pleiotropic, although we applied multiple sensitivity analyses, including 406 the heterogeneity test, MR-Egger, and WM method. Second, a limitation of this MR study is that 407 the effect of endogenous PUFAs may be different from the effect of dietary PUFAs, and our study 408 did not directly examine dietary PUFAs. However, leveraging genetic instruments yields novel 409 insights and minimizes the measurement error from self-reported dietary consumption in nutrition 410 studies. Third, another limitation is that the population controls were utilized with no information 411 on COVID-19 status in three COVID-19 GWAS used in our primary analysis, including the HGI 412 A2, B2, and C2 studies. To mitigate this issue, we also utilized the HGI B1 study, which is another 413 GWAS of COVID-19 using non-hospitalized patients as the control group. Fourth, in the 414 observational study, UK Biobank recruited healthier individuals and thus may not be 415 representative of the general population. Fifth, the NMR-based measurements of plasma PUFAs 416 were collected over ten years before the COVID-19 pandemic, and the time lag likely attenuates 417 the magnitude of association. Sixth, our observational study could be affected by ascertainment 418 bias in differential healthcare seeking and testing. Seventh, our findings might not be extrapolated 419 to other ethnicities because the study only focused on participants of European descent. Eighth, 420 our study can not thoroughly explain the mechanisms. Further mechanistic research is necessary 421 to investigate the biological pathways underpinning the roles of PUFAs in severe COVID-19.

422

423	In conclusion, our observational analysis in a prospective cohort shows that total PUFAs, omega-
424	3 PUFAs, omega-6 PUFAs, DHA, and LA are inversely associated with the risk of severe COVID-
425	19. Omega-3 and DHA may also be protective against SARS-CoV-2. A higher omega-6/omega-3
426	ratio has adverse effects on both COVID-19 susceptibility and severity. Our MR study further
427	suggests a possible causal role of AA and DPA-n3 in reducing the risk of severe COVID-19. Our
428	findings call for further studies into the mechanistic roles of PUFAs in COVID-19. They also
429	support the possible usage of circulating PUFA levels as biomarkers for identifying high-risk
430	individuals and as therapeutic targets for managing COVID-19 patients.

431 References

432 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. 1. 433 A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 434 2020;382(8):727-33. doi: 10.1056/NEJMoa2001017. 435 World Health Organization. Coronavirus disease 2019 (COVID-19) report. 2021. 2. 436 3. James PT, Ali Z, Armitage AE, Bonell A, Cerami C, Drakesmith H, Jobe M, Jones KS, 437 Liew Z, Moore SE, et al. The Role of Nutrition in COVID-19 Susceptibility and Severity of 438 Disease: A Systematic Review. J Nutr 2021;151(7):1854-78. doi: 10.1093/jn/nxab059. 439 4. Akhtar S, Das JK, Ismail T, Wahid M, Saeed W, Bhutta ZA. Nutritional perspectives for 440 the prevention and mitigation of COVID-19. Nutr Rev 2021;79(3):289-300. doi: 441 10.1093/nutrit/nuaa063. 442 5. Torrinhas RS, Calder PC, Lemos GO, Waitzberg DL. Parenteral fish oil: An adjuvant 443 pharmacotherapy for coronavirus disease 2019? Nutrition 2021;81:110900. doi: 444 10.1016/j.nut.2020.110900. 445 Das UN. Essential fatty acids and their metabolites in the pathobiology of (coronavirus 6. 446 disease 2019) COVID-19. Nutrition 2021;82:111052. doi: 10.1016/j.nut.2020.111052. 447 Kothapalli KSD, Park HG, Brenna JT. Polyunsaturated fatty acid biosynthesis pathway 7. 448 and genetics, implications for interindividual variability in prothrombotic, inflammatory 449 conditions such as COVID-19(,, bigstar, bigstar bigstar). Prostaglandins Leukot Essent Fatty 450 Acids 2020;162:102183. doi: 10.1016/j.plefa.2020.102183. 451 Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. Immunity 8. 452 2020;53(1):19-25. doi: 10.1016/j.immuni.2020.06.017. 453 Zapata BR, Muller JM, Vasquez JE, Ravera F, Lago G, Canon E, Castaneda D, Pradenas 9. 454 M, Ramirez-Santana M. Omega-3 Index and Clinical Outcomes of Severe COVID-19: 455 Preliminary Results of a Cross-Sectional Study. Int J Environ Res Public Health 2021;18(15). 456 doi: 10.3390/ijerph18157722. 457 Asher A, Tintle NL, Myers M, Lockshon L, Bacareza H, Harris WS. Blood omega-3 fatty 10. 458 acids and death from COVID-19: A pilot study. Prostaglandins Leukot Essent Fatty Acids 459 2021;166:102250. doi: 10.1016/j.plefa.2021.102250. 460 Dierckx T, van Elslande J, Salmela H, Decru B, Wauters E, Gunst J, Van Herck Y, 11. 461 CONTAGIOUS-consortium t, Wauters J, Stessel B, et al. The metabolic fingerprint of COVID-462 19 severity. 2020:2020.11.09.20228221. doi: 10.1101/2020.11.09.20228221 %J medRxiv. 463 Perez-Torres I, Guarner-Lans V, Soria-Castro E, Manzano-Pech L, Palacios-Chavarria A, 12. 464 Valdez-Vazquez RR, Dominguez-Cherit JG, Herrera-Bello H, Castillejos-Suastegui H, Moreno-465 Castaneda L, et al. Alteration in the Lipid Profile and the Desaturases Activity in Patients With 466 Severe Pneumonia by SARS-CoV-2. Front Physiol 2021;12:667024. doi: 467 10.3389/fphys.2021.667024. 468 Julkunen H, Cichonska A, Slagboom PE, Wurtz P, Nightingale Health UKBI. Metabolic 13. 469 biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the 470 general population. Elife 2021;10. doi: 10.7554/eLife.63033. 14. 471 Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute 472 to understanding environmental determinants of disease? Int J Epidemiol 2003;32(1):1-22. doi: 473 10.1093/ije/dyg070. 474 15. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation 475 to assess potential benefit of clinical intervention. BMJ 2012;345:e7325. doi: 476 10.1136/bmj.e7325.

- 477 16. Ponsford MJ, Gkatzionis A, Walker VM, Grant AJ, Wootton RE, Moore LSP, Fatumo S,
- 478 Mason AM, Zuber V, Willer C, et al. Cardiometabolic Traits, Sepsis, and Severe COVID-19: A
- 479 Mendelian Randomization Investigation. Circulation 2020;142(18):1791-3. doi:
- 480 10.1161/CIRCULATIONAHA.120.050753.
- 481 Sun Y, Zhou J, Ye K. White Blood Cells and Severe COVID-19: A Mendelian 17.
- 482 Randomization Study. J Pers Med 2021;11(3). doi: 10.3390/jpm11030195.
- 483 Sun Y, Zhou J, Ye K. Extensive Mendelian randomization study identifies potential 18.
- 484 causal risk factors for severe COVID-19. Communications Medicine 2021. doi: 10.1038/s43856-485 021-00061-9.
- 486 19. Li S, Hua X. Modifiable lifestyle factors and severe COVID-19 risk: a Mendelian
- 487 randomisation study. BMC Med Genomics 2021;14(1):38. doi: 10.1186/s12920-021-00887-1.
- 488 Yuan T, Si S, Li Y, Li W, Chen X, Liu C, Li J, Wang B, Hou L, Liu Y, et al. Roles for 20. 489 circulating polyunsaturated fatty acids in ischemic stroke and modifiable factors: a Mendelian
- 490 randomization study. Nutr J 2020;19(1):70. doi: 10.1186/s12937-020-00582-4.
- 491 Zhao JV, Schooling CM. The role of linoleic acid in asthma and inflammatory markers: a 21. 492 Mendelian randomization study. Am J Clin Nutr 2019;110(3):685-90. doi: 10.1093/ajcn/nqz130.
- 493 22. Ma M, Yang F, Wang Z, Bao Q, Shen J, Xie X. Association of plasma polyunsaturated 494 fatty acids with arterial blood pressure: A Mendelian randomization study. Medicine (Baltimore)
- 495 2021;100(3):e24359. doi: 10.1097/MD.00000000024359.
- 496 Zhang T, Zhao JV, Schooling CM. The associations of plasma phospholipid arachidonic 23.
- 497 acid with cardiovascular diseases: A Mendelian randomization study. EBioMedicine 498 2021;63:103189. doi: 10.1016/j.ebiom.2020.103189.
- 499 24. Park S, Lee S, Kim Y, Lee Y, Kang M, Kim K, Kim Y, Han S, Lee H, Lee J, et al. Causal 500 Effects of Serum Levels of n-3 or n-6 Polyunsaturated Fatty Acids on Coronary Artery Disease: 501 Mendelian Randomization Study. Nutrients 2021;13(5). doi: 10.3390/nu13051490.
- 502 25. Liao LZ, Li WD, Liu Y, Li JP, Zhuang XD, Liao XX. Exploring the causal pathway from
- 503 omega-6 levels to coronary heart disease: A network Mendelian randomization study. Nutr 504
- Metab Cardiovasc Dis 2020;30(2):233-40. doi: 10.1016/j.numecd.2019.09.013.
- 505 Zhao JV, Schooling CM. Effect of linoleic acid on ischemic heart disease and its risk 26. 506 factors: a Mendelian randomization study. BMC Med 2019;17(1):61. doi: 10.1186/s12916-019-1293-x. 507
- 508 27. Livanage UE, Ong JS, An J, Gharahkhani P, Law MH, MacGregor S. Mendelian
- 509 Randomization Study for Genetically Predicted Polyunsaturated Fatty Acids Levels on Overall
- 510 Cancer Risk and Mortality. Cancer Epidemiol Biomarkers Prev 2019;28(6):1015-23. doi:
- 511 10.1158/1055-9965.EPI-18-0940.
- 512 Lemaitre RN, Tanaka T, Tang W, Manichaikul A, Foy M, Kabagambe EK, Nettleton JA, 28.
- 513 King IB, Weng LC, Bhattacharya S, et al. Genetic loci associated with plasma phospholipid n-3
- 514 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium.
- 515 PLoS Genet 2011;7(7):e1002193. doi: 10.1371/journal.pgen.1002193.
- 516 Guan W, Steffen BT, Lemaitre RN, Wu JHY, Tanaka T, Manichaikul A, Foy M, Rich 29.
- 517 SS, Wang L, Nettleton JA, et al. Genome-wide association study of plasma N6 polyunsaturated
- 518 fatty acids within the cohorts for heart and aging research in genomic epidemiology consortium.
- 519 Circ Cardiovasc Genet 2014;7(3):321-31. doi: 10.1161/CIRCGENETICS.113.000208.
- 520 Tintle NL, Pottala JV, Lacey S, Ramachandran V, Westra J, Rogers A, Clark J, Olthoff 30.
- 521 B, Larson M, Harris W, et al. A genome-wide association study of saturated, mono- and

- 522 polyunsaturated red blood cell fatty acids in the Framingham Heart Offspring Study.
- 523 Prostaglandins Leukot Essent Fatty Acids 2015;94:65-72. doi: 10.1016/j.plefa.2014.11.007.
- 524 31. The COVID-10 Host Genetics Initiative. Mapping the human genetic architecture of 525 COVID-19. Nature 2021. doi: 10.1038/s41586-021-03767-x.
- 526 32. Davey Smith G, Davies N, Dimou N, Egger M, Gallo V, Golub R, Higgins J, Langenberg
- 527 C, Loder E, Richards J, et al. STROBE-MR: Guidelines for strengthening the reporting of
- 528 Mendelian randomization studies. PeerJ Preprints 2019;7:e27857v1. doi:
- 529 10.7287/peerj.preprints.27857v1.
- 530 33. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green
- J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a wide
- range of complex diseases of middle and old age. PLoS Med 2015;12(3):e1001779. doi:
 10.1371/journal.pmed.1001779.
- 534 34. Wurtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M.
- 535 Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology:
- 536 A Primer on -Omic Technologies. Am J Epidemiol 2017;186(9):1084-96. doi:
- 537 10.1093/aje/kwx016.
- 538 35. Armstrong J, Rudkin JK, Allen N, Crook DW, Wilson DJ, Wyllie DH, O'Connell AM.
- 539 Dynamic linkage of COVID-19 test results between Public Health England's Second Generation
- Surveillance System and UK Biobank. Microb Genom 2020;6(7). doi: 10.1099/mgen.0.000397.
 36. Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt
- 542 2014;34(5):502-8. doi: 10.1111/opo.12131.
- 543 37. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in 544 Mendelian randomization studies. Int J Epidemiol 2011;40(3):755-64. doi: 10.1093/ije/dyr036.
- 545 38. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with
- multiple genetic variants using summarized data. Genet Epidemiol 2013;37(7):658-65. doi:
 10.1002/gepi.21758.
- 39. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
 instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol
 2015;44(2):512-25. doi: 10.1093/ije/dyv080.
- 40. Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M, Hartwig F,
- 552 Holmes M, Minelli C, Relton C, et al. Guidelines for performing Mendelian randomization
- 553 investigations [version 2; peer review: 1 approved, 1 approved with reservations]. Wellcome
- 554 Open Research 2020;4(186). doi: 10.12688/wellcomeopenres.15555.2.
- Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
- 557 Epidemiol 2016;40(4):304-14. doi: 10.1002/gepi.21965.
- 558 42. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian
- randomisation studies with summary data and a continuous outcome. Stat Med
- 560 2015;34(21):2926-40. doi: 10.1002/sim.6522.
- 561 43. Bowden J, Spiller W, Del Greco MF, Sheehan N, Thompson J, Minelli C, Davey Smith
- 562 G. Improving the visualization, interpretation and analysis of two-sample summary data
- 563 Mendelian randomization via the Radial plot and Radial regression. Int J Epidemiol
- 564 2018;47(4):1264-78. doi: 10.1093/ije/dyy101.
- 565 44. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S,
- 566 Bowden J, Langdon R, et al. The MR-Base platform supports systematic causal inference across
- 567 the human phenome. Elife 2018;7. doi: 10.7554/eLife.34408.

- 568 45. Doaei S, Gholami S, Rastgoo S, Gholamalizadeh M, Bourbour F, Bagheri SE, Samipoor
- 569 F, Akbari ME, Shadnoush M, Ghorat F, et al. The effect of omega-3 fatty acid supplementation
- 570 on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized
- 571 clinical trial. J Transl Med 2021;19(1):128. doi: 10.1186/s12967-021-02795-5.
- 572 46. Chiang N, Serhan CN. Specialized pro-resolving mediator network: an update on
- 573 production and actions. Essays Biochem 2020;64(3):443-62. doi: 10.1042/EBC20200018.
- 574 47. Das UN. Can Bioactive Lipid Arachidonic Acid Prevent and Ameliorate COVID-19?
- 575 Medicina (Kaunas) 2020;56(9). doi: 10.3390/medicina56090418.
- 576 48. Yan B, Chu H, Yang D, Sze KH, Lai PM, Yuan S, Shuai H, Wang Y, Kao RY, Chan JF,
- 577 et al. Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells:
- 578 Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. Viruses 579 2019;11(1). doi: 10.3390/v11010073.
- 580 49. Toelzer C, Gupta K, Yadav SKN, Borucu U, Davidson AD, Kavanagh Williamson M,
- 581 Shoemark DK, Garzoni F, Staufer O, Milligan R, et al. Free fatty acid binding pocket in the
- 582 locked structure of SARS-CoV-2 spike protein. Science 2020;370(6517):725-30. doi:
- 583 10.1126/science.abd3255.
- 584 50. Goc A, Niedzwiecki A, Rath M. Polyunsaturated omega-3 fatty acids inhibit ACE2-
- 585 controlled SARS-CoV-2 binding and cellular entry. Sci Rep 2021;11(1):5207. doi:
- 586 10.1038/s41598-021-84850-1.
- 587

588 Acknowledgments

- 589 Our study was approved by the University of Georgia Institutional Review Board and the UK
- 590 Biobank consortium (application no. 48818). We thank the investigators of the COVID-19 Host
- 591 Genetics Initiative for sharing the GWAS summary statistics.
- 592
- 593 The authors' responsibilities were as follows—YS and KY: designed the study, provided statistical
- advice, and interpreted the data; YS: performed data analysis and prepared visualizations; YS, RC,
- and AR: provided material support during the study; YS: wrote the paper; KY: critically revised
- the paper; and all authors: read and approved the final manuscript and took responsibility for the
- 597 integrity of the work as a whole. The authors report no conflicts of interest.
- 598

599 Data availability

- 600 The COVID-19 data (GWAS summary statistics) used in this study are freely accessible in the
- 601 COVID-19 Host Genetics Initiative (<u>https://www.covid19hg.org/</u>). The code for the analyses is
- 602 available at <u>https://github.com/yitangsun/COVID19_PUFA_MR</u>.

603

604 Notes

Research reported in this publication was supported by the University of Georgia Research Foundation and by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM143060. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the University of Georgia.

610

611 Supplemental Tables 1–29 are available from the "Supplementary data" link in the online posting 612 of the article and from the same link in the online table of contents at 613 https://academic.oup.com/ajcn/.

614

615 Abbreviations used: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory 616 syndrome coronavirus 2; PUFAs, polyunsaturated fatty acids; LA: linoleic acid; EPA, 617 eicosapentaenoic acid; DHA, docosahexaenoic acid; RBC, red blood cell; AA, arachidonic acid; 618 MR, Mendelian randomization; BMI, body mass index; GWAS, genome-wide association studies; 619 HGI, COVID-19 Host Genetics Initiative; FHS, Framingham Heart Study; STROBE, 620 strengthening the reporting of observational studies in epidemiology; STROBE-MR, strengthening 621 the reporting of Mendelian randomization studies; ALA, α -Linolenic acid; DPA-n3, 622 docosapentaenoic acid; GLA, y-Linoleic acid; DGLA, dihomo-y-linoleic acid; DTA, 623 docosatetraenoic acid; NMR, nuclear magnetic resonance; SD, standard deviation; SNPs, single nucleotide polymorphisms; LD, linkage disequilibrium; OR, odds ratio; IVW, inverse variance-624 625 weighted; WM, weighted median; CI, confidence interval; PGs, prostaglandins; HCoV-229E, 626 human coronavirus 229E; MERS-CoV, Middle East respiratory syndrome coronavirus.

Tables

TABLE 1 Characteristics of the UK Biobank participants at baseline¹

	England, Scotland, and Wales					
Characteristics	Hospitalized COVID-19	Non-hospitalized COVID-19	Test positive	Test negative	Test positive	Test negative
Participants, n	4,209	12,240	16,449	76,307	17,395	86,717
Participants with plasma PUFA measures, <i>n</i>	970	2,903	3,873	18,293	4,101	20,626
Age, y	59 [40-70]	51 [40-70]	52 [40-70]	59 [40-70]	52 [40-70]	59 [40-70]
Females, n (%)	445 (46)	1,559 (54)	2,004 (52)	9,771 (53)	2,123 (52)	11,145 (54)
Body mass index, kg/m2 (SD)	29.55 (5.61)	27.96 (4.94)	28.36 (5.16)	27.69 (4.88)	28.36 (5.14)	27.71 (4.89)
PUFAs, mmol/l (SD)	4.82 (0.81)	4.92 (0.78)	4.89 (0.79)	4.97 (0.804)	4.89 (0.78)	4.96 (0.801)
Omega-3 PUFAs, mmol/l (SD)	0.48 (0.203)	0.49 (0.205)	0.49 (0.204)	0.53 (0.22)	0.49 (0.203)	0.53 (0.22)
DHA, mmol/l (SD)	0.21 (0.07)	0.22 (0.08)	0.22 (0.08)	0.24 (0.08)	0.22 (0.08)	0.23 (0.08)
Omega-6 PUFAs, mmol/l (SD)	4.34 (0.699)	4.42 (0.66)	4.401 (0.67)	4.44 (0.68)	4.402 (0.67)	4.44 (0.68)
LA, mmol/l (SD)	3.29 (0.698)	3.39 (0.65)	3.37 (0.67)	3.39 (0.69)	3.37 (0.66)	3.39 (0.68)
	1					

1 Values are numbers (%) for categorical variables, mean (SD) or medians [range] for continuous variables. PUFAs, polyunsaturated fatty acids; DHA, docosahexaenoic acid; LA linoleic acid.

COVID-19 severity							COVID-19 susceptibility					
	Hosp	oitalized	vs. Non-	Hospitalized vs. Test		Test positive vs. Test			Test positive vs. Test negative			
	hospitalized $(n = 3,873)$ negative $(n = 19,263)$			nega	tive $(n = 2)$	22,166) ²	$(n = 24,727)^3$					
Plasma PUFA measures	β	SE	Р	β	SE	Р	β	SE	Р	β	SE	Р
PUFAs	-0.139	0.043	0.0012	-0.127	0.037	0.0005	-0.029	0.019	0.1285	-0.027	0.018	0.1337
Omega-3 PUFAs	-0.140	0.044	0.0013	-0.197	0.040	8.1×10 ⁻⁷	-0.083	0.020	4.3×10 ⁻⁵	-0.082	0.019	2.3×10 ⁻⁵
DHA	-0.176	0.045	8.9×10 ⁻⁵	-0.247	0.042	4.6×10 ⁻⁹	-0.098	0.021	3.0×10 ⁻⁶	-0.097	0.020	1.4×10^{-6}
Omega-6 PUFAs	-0.121	0.043	0.0047	-0.090	0.036	0.0121	-0.010	0.019	0.6183	-0.008	0.018	0.6656
LA	-0.113	0.043	0.0079	-0.082	0.036	0.0228	-0.007	0.019	0.7289	-0.006	0.018	0.7299
Omega-6/omega-3	0.114	0.042	0.0061	0.124	0.029	1.5×10 ⁻⁵	0.053	0.018	0.0030	0.058	0.017	0.0005

TABLE 2 Associations of PUFAs concentrations with COVID-19 susceptibility and severity¹

1 Effect sizes (β) per SD increase in the exposure, SEs, and *P* values were obtained from the logistic regression analysis of COVID-19 susceptibility and severity. All models were adjusted for age, sex, ethnicity, BMI, Townsend deprivation index, and assessment center. PUFA, polyunsaturated fatty acids; DHA, docosahexaenoic acid; LA linoleic acid.

2 Data from England only.

3 Data from England, Scotland, and Wales.

Figure Legends

Figure 1. Flowchart of the UK Biobank participants from recruitment to inclusion in the observational analysis.

Figure 2. Mendelian randomization estimates of the effects of polyunsaturated fatty acids on COVID-19 severity risk. (A) Mendelian randomization analysis based on the release 5 HGI A2. (B) Mendelian randomization analysis based on the release 5 HGI B2. (C) Mendelian randomization analysis based on the release 5 HGI B1. Odds ratios are scaled to a genetically predicted SD increase in polyunsaturated fatty acids. Associations with p-value < 0.05 were indicated with diamonds, while others with squares. Detailed summary statistics are available in Supplemental Tables 6–8. PUFA, polyunsaturated fatty acid; ALA, α -Linolenic acid; LA: linoleic acid; GLA, γ-Linoleic acid; DGLA, dihomo-γ-linoleic acid; AA, arachidonic acid; DPA-n3, docosapentaenoic acid; DTA, docosatetraenoic acid; DHA, docosahexaenoic acid; OR, odds ratio. Figure 3. Mendelian randomization estimates of the effects of polyunsaturated fatty acids on COVID-19 susceptibility risk based on the release 5 HGI C2. Odds ratios are scaled to a genetically predicted SD increase in polyunsaturated fatty acids. Associations with p-value < 0.05were indicated with diamonds, while others with squares. Detailed summary statistics are available in Supplemental Table 9. PUFA, polyunsaturated fatty acid; ALA, α -Linolenic acid; LA: linoleic acid; GLA, γ-Linoleic acid; DGLA, dihomo-γ-linoleic acid; AA, arachidonic acid; DPA-n3, docosapentaenoic acid; DTA, docosatetraenoic acid; DHA, docosahexaenoic acid; OR, odds ratio.

Figures

FIGURE 1



FIGURE 2

Plasma

DTA Red blood cell

DHA Plasma

Red blood cell

0.5 1 1.5 2

Odds ratio

Α	HGI A2			в	HGI B2			
Exposure		OR [95% CI]	P-value	Exposure			OR [95% CI]	P-value
PUFA				PUFA				
ALA				ALA				
Plasma		1.11 [0.93–1.33]	0.230	Plasma			1.11 [0.98-1.25]	0.098
Red blood cell LA		1.05 [0.75–1.47]	0.780	Red blood cell LA			1.13 [0.90–1.42]	0.291
Plasma	.	1.08 [1.00-1.16]	0.053	Plasma	•		1.06 [1.01-1.11]	0.015
Red blood cell GLA	-	1.04 [0.89–1.21]	0.611	Red blood cell GLA	-		1.08 [0.98-1.20]	0.126
Plasma	-8-	0.90 [0.79-1.02]	0.094	Plasma	•		0.89 [0.87-0.91]	6.60e-20
Red blood cell DGLA		0.96 [0.73–1.26]	0.780	Red blood cell DGLA	-8-		0.91 [0.76–1.09]	0.291
Plasma	•	1.07 [1.05-1.09]	7.13e-11	Plasma	-		1.05 [0.97-1.13]	0.231
Red blood cell AA		1.02 [0.83–1.24]	0.870	Red blood cell AA	+		1.01 [0.93–1.10]	0.828
Plasma	•	0.96 [0.94-0.99]	0.007	Plasma	•		0.96 [0.96-0.97]	3.23e-20
Red blood cell DPA-n3	•	0.97 [0.94–1.00]	0.048	Red blood cell DPA-n3	•		0.95 [0.93-0.97]	1.32e-05
Plasma	→	0.89 [0.81-0.99]	0.026	Plasma	•		0.93 [0.92-0.95]	4.73e-20
Red blood cell DTA	-	0.79 [0.63-0.99]	0.041	Red blood cell DTA	•		0.88 [0.82-0.94]	9.30e-05
Red blood cell DHA		0.91 [0.74–1.12]	0.382	Red blood cell DHA	-		0.90 [0.79–1.04]	0.148
Plasma	· · · · · · · · · · · · · · · · · · ·	1.60 [1.06–2.42]	0.026	Plasma		_	1.18 [0.88–1.56]	0.269
	0.5 1 1.5 2 Odds ratio	!			0.5 1 1.5 Odds ratio	2		
С	HGI B1							
Exposure		OR [95% CI]	P-value					
PUFA					<i>p</i> -value < 0.05			
ALA					p-value ≥ 0.05			
Plasma	_	1.24 [1.01-1.51]	0.038	-				
Red blood cell LA		1.44 [0.98–2.10]	0.061					
Plasma		1.12 [0.97-1.29]	0.117					
Red blood cell GLA		1.26 [1.05–1.50]	0.011					
Plasma	•	0.77 [0.72-0.82]	2.82e-17					
Red blood cell DGLA		0.75 [0.55–1.01]	0.061					
Plasma	—B —	1.08 [0.85-1.36]	0.528					
Red blood cell AA		1.01 [0.96–1.06]	0.840					
Plasma	•	0.92 [0.87-0.98]	0.008					
Red blood cell DPA-n3	•	0.84 [0.83–0.85]	8.57e-130					

0.88 [0.83-0.93]

0.76 [0.59-0.98]

0.78 [0.62-0.98]

1.11 [0.69-1.79]

3.59e-06

0.036

0.034

0.674

FIGURE 3

		HGI C2			
Exposure				OR [95% CI]	P-value
PUFA					
ALA					
Plasma				1.01 [0.95–1.08]	0.697
Red blood cell				1.00 [0.89–1.12]	0.994
LA					
Plasma		+		1.01 [0.99–1.03]	0.430
Red blood cell				1.00 [0.95–1.06]	0.993
GLA					
Plasma				0.99 [0.95–1.04]	0.775
Red blood cell				1.00 [0.91–1.10]	0.994
DGLA					
Plasma		•		1.01 [1.00–1.02]	0.031
Red blood cell		•		1.01 [1.00–1.02]	0.007
AA					
Plasma				1.00 [0.98–1.01]	0.576
Red blood cell		-		1.02 [1.00–1.03]	0.050
DPA-n3					
Plasma		-		1.00 [0.98–1.01]	0.579
Red blood cell		•		0.99 [0.98–0.99]	6.05e-136
DTA					
Red blood cell				0.99 [0.92–1.06]	0.794
DHA					
Plasma	_			1.04 [0.90–1.21]	0.574
	•	-		n	-value < 0.05
	0.8		1.2		
		Odds ratio		— <i>p</i> -	-value ≥ 0.05

Supplemental Tables

Supplemental Table 1. Notable Mendelian randomization studies of polyunsaturated fatty acids. Supplemental Table 2. STROBE Statement—checklist of items that should be included in reports of cohort studies.

Supplemental Table 3. STROBE-MR checklist.

Supplemental Table 4. Genetic instruments for plasma polyunsaturated fatty acids.

Supplemental Table 5. Significant SNPs for red blood cell polyunsaturated fatty acids.

Supplemental Table 6. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 severity based on the release 5 HGI A2. Supplemental Table 7. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 severity based on the release 5 HGI B2. Supplemental Table 8. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 severity based on the release 5 HGI B1. Supplemental Table 9. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 severity based on the release 5 HGI B1. Supplemental Table 9. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 susceptibility based on the release 5 HGI B1. Supplemental Table 9. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 susceptibility based on the release 5 HGI B1. Supplemental Table 9. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 susceptibility based on the release 5 HGI C2.

Supplemental Table 10. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 severity based on the release 4 HGI A2. Supplemental Table 11. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 severity based on the release 4 HGI B2. Supplemental Table 12. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 severity based on the release 4 HGI B2.

Supplemental Table 13. Forward Mendelian randomization estimates of associations of genetically predicted polyunsaturated fatty acids with COVID-19 susceptibility based on the release 4 HGI C2.

Supplemental Table 14. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 5 HGI A2 (COVID-19 SNP P < 5e-8).

Supplemental Table 15. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 5 HGI B2 (COVID-19 SNP P < 5e-8).

Supplemental Table 16. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 5 HGI B1 (COVID-19 SNP P < 5e-8).

Supplemental Table 17. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 susceptibility with polyunsaturated fatty acids based on the release 5 HGI C2 (COVID-19 SNP P < 5e-8).

Supplemental Table 18. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 5 HGI A2 (COVID-19 SNP P < 5e-6).

Supplemental Table 19. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 5 HGI B2 (COVID-19 SNP P < 5e-6).

Supplemental Table 20. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 5 HGI B1 (COVID-19 SNP P < 5e-6).

Supplemental Table 21. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 susceptibility with polyunsaturated fatty acids based on the release 5 HGI C2 (COVID-19 SNP P < 5e-6).

Supplemental Table 22. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 4 HGI A2 (COVID-19 SNP P < 5e-8).

Supplemental Table 23. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 4 HGI B2 (COVID-19 SNP P < 5e-8).

Supplemental Table 24. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 4 HGI B1 (COVID-19 SNP P < 5e-8).

Supplemental Table 25. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 susceptibility with polyunsaturated fatty acids based on the release 4 HGI C2 (COVID-19 SNP P < 5e-8).

Supplemental Table 26. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 4 HGI A2 (COVID-19 SNP P < 5e-6).

Supplemental Table 27. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 4 HGI B2 (COVID-19 SNP P < 5e-6).

Supplemental Table 28. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 severity with polyunsaturated fatty acids based on the release 4 HGI B1 (COVID-19 SNP P < 5e-6).

Supplemental Table 29. Reverse Mendelian randomization estimates of associations of genetically predicted COVID-19 susceptibility with polyunsaturated fatty acids based on the release 4 HGI C2 (COVID-19 SNP P < 5e-6).